CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 3,058 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03937245
NCT03937245N/ACompleted
CompareCT.gov

Epidemiology and Determinants of Outcomes of Hospital Acquired Blood Stream Infections in the Intensive Care: the Eurobact II Multinational Cohort Study

Outcome Rea·observational·Posted May 3, 2019·Updated Sep 9, 2021

In Brief

An observational study for Bacteremia and 3 related conditions. Completed, enrolled 3,058 participants across 2 sites in 2 countries.

Detailed Summary

Eurobact II will investigate the mortality and morbidity of hospital-acquired blood stream infections in patients treated in intensive care units (ICU). It will investigate the effects of the micro-organism and its characteristics, such as type and resistance to antibiotics on the infection and its consequences. It will also investigate the effects of the antibiotics and other treatments on survival of patients. Eurobact II will include patients from multiple ICUs in multiple countries.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBacteremia, Sepsis, Hospital Acquired Condition, Resistance Bacterial
CountriesAustralia, France
CollaboratorsEuropean Society of Intensive Care Medicine, European Society of Clinical Microbiology and Infectious Diseases, Institut National de la Santé Et de la Recherche Médicale, France

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedMay 3, 2019
Enrollment StartAug 30, 2019
Primary CompletionJun 2, 2021
Study CompletionJun 3, 2021
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 7.2 years ago